Continuous Glucose Monitoring

Test your pharmacy news knowledge with our weekly quiz.

Dexcom's Stelo will be available in summer 2024.

If approved, KnowU will become the world’s first non-invasive blood glucose monitor introduced to the global marketplace.

Many patients with the condition continue to experience severe hypoglycemic events even with the use of continuous glucose monitors and other disease management tools.

Despite previously suggested benchmarks, investigators found that spending less time-in-range (TIR) can still improve maternal and perinatal outcomes among pregnant patients with type 1 diabetes (T1D).

Although continous glucose monitors (CGMs) have often been tailored to patients with type 1 diabetes, data elicited by these technologies add value to the management of type 2 diabetes by offering insights into patients’ unique responses to food, activity, medications, and more.

Three posters being presented at the Society for Maternal-Fetal Medicine 44th Annual Pregnancy Meeting examined the impact of continuous glucose monitoring on pregnancy outcomes.

Real-time continuous glucose monitoring (CGM) demonstrated benefits associated with time in range, hypoglycemia, and hyperglycemia in patients with type 1 diabetes (T1D).

A Q&A with Kevin Malloy, PharmD, BCPS, on how diabetes technology has improved and how it can help pregnant people manage their disease.

A new study found that glucose monitoring devices can help significantly improve the sleep of both parents and children.

Increased health care access to devices like the continuous glucose monitor (CGM) could improve health outcomes for underserved patients who may otherwise be hindered from their use.

A new study found that over 90% of patients and providers said they found the continuous glucose monitoring useful.

The OPTIMAL trial assessed the effects of continuous glucose monitoring compared with HbA1c-guided glycemic control on the progression of coronary atherosclerosis in patients with type 2 diabetes mellitus.

The use of continuous glucose monitoring may improve outcomes in patients with cystic fibrosis-related diabetes.

Researchers assessed the reproducibility of at-home CGM acquisitions with mixed meal tolerance tests among patients with CF-related diabetes who were not treated with insulin.

Patients with type 1 diabetes who use technologies for glycemic management may perceive these devices as important for glucose monitoring and emotion well-being, but affordability remains a significant barrier.

There has been growing evidence around the potential for the success of remote diabetes care and CGM technology use.

For noncritically ill hospitalized patients with diabetes, CGM is a reliable tool to improve glycemic control. However, more randomized studies are needed to assess these results in diverse populations.

Hybrid closed-loop insulin therapy adjusts insulin doses every 10 to 12 minutes by using a smartphone algorithm to communicate with continuous glucose monitoring devices and insulin pump systems.

A new study found that participants reported improved glycemic control and improved quality of life with smartwatch-integrated, do-it-yourself continuous glucose monitoring.

The 3 most common issues associated with higher satisfaction were “makes adjusting insulin easier,” “helps to keep low blood sugars from happening,” and “makes me feel safer knowing that I will be warned about low blood sugar before it happens.”

A 1-year observational follow-up of a 3-month randomized controlled trial provides insight into the benefits of advanced hybrid closed-loop system use in people with type 1 diabetes using multiple daily injections and self-monitoring of blood glucose.

Widespread use of continuous glucose monitoring was not found to attenuate the association between impaired awareness of hypoglycemia and diabetes-related distress.

Although investigators found a lack of strong evidence to support CGM programs in community pharmacy settings, studies in ambulatory care settings suggest that these programs are both feasible and beneficial.

Device adoption among minority patients with type 1 and type 2 diabetes remains low due to socioeconomic disparities.

Numerous tools, technology platforms, and interventions have been developed to help teens with the difficult emotional and physical weight of managing the disease.